Pyridostigmine Bromide
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00545 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 21 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | myasthenia gravis with thymus hyperplasia | KG + DL |
| 2 | neonatal myasthenia gravis | KG + DL |
| 3 | autoimmune disease of peripheral nervous system | KG + DL |
| 4 | myasthenia, limb-girdle, autoimmune | KG + DL |
| 5 | disease of receptor activity | KG + DL |
| 6 | hypersplenism (disease) | KG + DL |
| 7 | atypical hemolytic-uremic syndrome with B factor anomaly | KG + DL |
| 8 | fetal akinesia deformation sequence | KG + DL |
| 9 | myasthenia, congenital, refractory to acetylcholinesterase inhibitors | KG + DL |
| 10 | congenital myasthenic syndrome with tubular aggregates | KG + DL |
| 11 | myasthenic syndrome, congenital, 25, presynaptic | KG + DL |
| 12 | myasthenic syndrome, congenital, 24, presynaptic | KG + DL |
| 13 | bronchitis | KG + DL |
| 14 | dermatitis | KG + DL |
| 15 | acrodermatitis chronica atrophicans | KG + DL |
| 16 | neonatal dermatomyositis | KG + DL |
| 17 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | KG + DL |
| 18 | hydroa vacciniforme, familial | KG + DL |
| 19 | amyopathic dermatomyositis | KG + DL |
| 20 | acne keloid | KG + DL |
| 21 | acute liver failure | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.